Tryp Therapeutics Announces Closing of Private Placement of Unsecured Convertible Debentures for Gross Proceeds of AUD$175,000
Tryp Therapeutics Announces Closing of Private Placement of Unsecured Convertible Debentures for Gross Proceeds of AUD$175,000
KELOWNA, BC / ACCESSWIRE / October 11, 2023 / Tryp Therapeutics Inc. ("Tryp" or the "Company") (CSE:TRYP), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs,is pleased to announce that it has closed its previously announced private placement (the "Private Placement") of unsecured convertible debentures (the "Debentures") to Tryp's newly appointed Chief Executive Officer, Jason Carroll, for aggregate gross proceeds of AUD$175,000.
不列顛哥倫比亞省基洛納/ACCESSWIRE/2023年10月11日/Tryp治療公司(“Tryp“或”公司“)(CSE：Tryp)，一家專注於開發靜脈注射裸蓋菇素(裸蓋菇素的活性代謝物)用於治療高度未得到滿足的醫療需求的疾病的臨床階段生物技術公司，高興地宣佈，它已經結束了之前宣佈的私募(The私 安放“)無抵押可轉換債券(”債券)出售給Tryp新任命的首席執行官Jason Carroll，總收益為175,000澳元。
The proceeds of the Private Placement will be used to advance Tryp's research and development programs and for general working capital purposes.
私募所得將用於推進Tryp的研發計劃和一般營運資金用途。
The securities issued in the Private Placement, including the Common Shares issuable on conversion of the Debentures, will be subject to a hold period of four months and one day from the closing date of the Private Placement in accordance with applicable securities laws.
根據適用的證券法，在私募中發行的證券，包括在債券轉換時可發行的普通股，將受自私募結束日起四個月零一天的持有期限制。
The Private Placement constitutes a "related party transaction" as such term is defined under Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions("MI 61-101") as Mr. Carroll is a related party of the Company. The Company has relied on exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101 in respect of related party participation in the Private Placement as neither the fair market value (as determined under MI 61-101) of the subject matter of, nor the fair market value of the consideration for, the transactions, insofar as they involved the related party, exceeded 25% of the Company's market capitalization (as determined under MI 61-101).
私募構成多邊文書61-101所界定的“關聯方交易”論少數群體證券持有人在特殊情況下的保護交易(“米其林61-101本公司依據MI 61-101第5.5(A)及5.7(1)(A)條所載有關關聯方參與私募的正式估值及少數股東批准規定豁免，因為涉及關聯方的交易標的的公平市價(按MI 61-101釐定)或代價的公平市價均不超過本公司市值(根據MI 61-101釐定)的25%。
About Tryp Therapeutics:
Tryp Treeutics公司簡介：
Tryp Therapeutics is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. Tryp's lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) that alleviates numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe. The Company has initiated a Phase 2a clinical trial for the treatment of Binge Eating Disorder at the University of Florida, where an interim analysis showed an average reduction in binge eating episodes of greater than 80%. The Company is also planning for Phase 2a clinical trials with the University of Michigan for the treatment of fibromyalgia and with Massachusetts General Hospital for the treatment of abdominal pain related to irritable bowel syndrome. An IND for both of these trials has been cleared by the FDA to proceed. Each of the studies are utilizing TRP-8802 (synthetic, oral psilocybin) to demonstrate efficacy in these indications. Where a preliminary clinical benefit is demonstrated, subsequent studies are expected to utilize TRP-8803 (IV-infused psilocin), which has the potential to further improve efficacy, safety and patient experience. For more information, please visit .
Tryp Treateutics是一家臨床階段的生物技術公司，專注於開發專有的新配方，用於給藥與心理療法相結合，以治療有未得到滿足的醫療需求的疾病。Tryp的Lead計劃TRP-8803是靜脈注射裸蓋菇素(裸蓋菇素的活性代謝物)的專利配方，可以緩解口服裸蓋菇素的許多缺點，包括：顯著縮短致幻狀態開始的時間，控制迷幻體驗的深度和持續時間，並將幹預的總持續時間減少到商業上可行的時間框架。該公司已經在佛羅裡達大學啟動了治療暴飲暴食障礙的2a期臨床試驗，中期分析顯示，暴飲暴食發作的平均減少超過80%。該公司還計劃與密歇根大學合作進行治療纖維肌痛的2a期臨床試驗，與馬薩諸塞州總醫院合作治療與腸易激綜合徵有關的腹痛。這兩項試驗的IND已經被FDA批准進行。每項研究都使用TRP-8802(合成的口服裸蓋菇素)來證明在這些適應症中的有效性。在初步的臨床益處被證明的地方，後續的研究有望利用Trp-8803(靜脈輸注的psiLocin)，它有可能進一步改善療效、安全性和患者體驗。欲瞭解更多資訊，請訪問。
Investor & Media Contact
投資者和媒體聯繫方式
Peter Molloy
Chief Business Officer
Tryp Therapeutics
pmolloy@tryptherapeutics.com
彼得·莫洛伊
首席商務官
Tryp治療公司
郵箱：pmolloy@trypTreateutics.com
Forward-Looking Information
前瞻性資訊
Certain information in this news release, including statements relating to the anticipated closing date of the Private Placement, constitutes forward-looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events.
本新聞稿中的某些資訊，包括與定向增發的預期結束日期有關的陳述，均為前瞻性資訊。在一些情況下，但不一定在所有情況下，前瞻性資訊可以通過使用前瞻性術語來識別，例如“計劃”、“目標”、“預期”或“不期望”、“預期”、“預期”、“機會存在”、“定位”、“估計”、“打算”、“假設”、“預期”或“不預期”或“相信”，或這些詞語和短語的變體或陳述某些行動、事件或結果“可能”、“可能”、“將”、“可能“將”或“將被採取”，“發生”或“將被實現”。此外，任何提及對未來事件或情況的預期、預測或其他描述的陳述都包含前瞻性資訊。含有前瞻性資訊的陳述不是歷史事實，而是代表管理層對未來事件的期望、估計和預測。
Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Tryp as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in greater detail in the "Risk Factors" section of Tryp's final prospectus available at . These factors are not intended to represent a complete list of the factors that could affect Tryp; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and Tryp expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.
前瞻性資訊必須基於許多意見、假設和估計，儘管Tryp在本新聞稿發佈之日認為這些意見、假設和估計是合理的，但這些意見、假設和估計會受到已知和未知的風險、不確定性、假設和其他因素的影響，這些因素可能會導致實際結果、活動水準、業績或成就與此類前瞻性資訊明示或暗示的結果、活動水準、業績或成就大不相同，包括但不限於Tryp最終招股說明書的“風險因素”部分更詳細地描述的因素，可在。這些因素並不是可能影響Tryp的因素的完整列表；但是，應該仔細考慮這些因素。不能保證這樣的估計和假設將被證明是正確的。本新聞稿中包含的前瞻性陳述是截至本新聞稿發佈之日作出的，Tryp明確表示不承擔任何義務來更新或更改包含任何前瞻性資訊或其背後的因素或假設的陳述，無論是由於新資訊、未來事件還是其他原因，除非法律要求。
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
加拿大證券交易所及其監管服務提供商均未對本新聞稿的充分性或準確性進行審查或承擔責任。
SOURCE: Tryp Therapeutics Inc.
資料來源：Tryp治療公司。
譯文內容由第三人軟體翻譯。